OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka-us.com

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

First Posted Date
2020-04-30
Last Posted Date
2024-06-26
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
150
Registration Number
NCT04369391
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Collaborative Neuroscience Research, LLC, Long Beach, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Woodland International Research Group, Little Rock, Arkansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Hassman Research Institute, Marlton, New Jersey, United States

and more 4 locations

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

First Posted Date
2020-02-06
Last Posted Date
2024-05-30
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
95
Registration Number
NCT04258839
Locations
๐Ÿ‡บ๐Ÿ‡ธ

APG Research, Orlando, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Cedar Health Research, Dallas, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dothan Behavioral Medicine Clinic, Dothan, Alabama, United States

and more 20 locations

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-01-27
Last Posted Date
2022-08-24
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
16
Registration Number
NCT04241965
Locations
๐Ÿ‡บ๐Ÿ‡ธ

For additional information regarding sites, contact 844-687-8522, Ormond Beach, Florida, United States

Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2019-12-04
Last Posted Date
2024-10-03
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
201
Registration Number
NCT04186403
Locations
๐Ÿ‡บ๐Ÿ‡ธ

For additional information regarding sites, contact 844-687-8522, New York, New York, United States

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder

First Posted Date
2019-11-22
Last Posted Date
2023-08-14
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
119
Registration Number
NCT04174365
Locations
๐Ÿ‡บ๐Ÿ‡ธ

For additional information regarding sites, Princeton, New Jersey, United States

Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder

First Posted Date
2019-11-22
Last Posted Date
2024-07-30
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
591
Registration Number
NCT04174170
Locations
๐Ÿ‡บ๐Ÿ‡ธ

For additional information regarding sites, contact 844-687-8522, New York, New York, United States

Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

First Posted Date
2019-10-11
Last Posted Date
2024-07-25
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
450
Registration Number
NCT04124614
Locations
๐Ÿ‡บ๐Ÿ‡ธ

For additional information regarding sites, contact 844-687-8522, San Diego, California, United States

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

Phase 3
Completed
Conditions
Interventions
First Posted Date
2019-10-04
Last Posted Date
2024-06-28
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
475
Registration Number
NCT04115319
Locations
๐Ÿ‡ท๐Ÿ‡ด

Spitalul Clinic de Psihiatrie "Prof. Dr. Alexandru Obregia", Sectia Psihiatrie XII, Bucuresti, Romania

๐Ÿ‡ท๐Ÿ‡บ

Saint Petersburg State Budgetary Institution of Healthcare "Psychoneurological Dispensay No 1", Saint Petersburg, Russian Federation

๐Ÿ‡ท๐Ÿ‡บ

State Budgetary Institution of Healthcare of Stavropol territory "Regional Specialization Psychiatry Hospital # 2", Stavropol, Russian Federation

and more 43 locations

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2019-10-01
Last Posted Date
2024-12-16
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
463
Registration Number
NCT04109950
Locations
๐Ÿ‡บ๐Ÿ‡ฆ

Research Site, Vinnytsia, Ukraine

A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

First Posted Date
2019-09-24
Last Posted Date
2024-07-18
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
332
Registration Number
NCT04100096
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Institute of Living Hartford Hospital, Hartford, Connecticut, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mindful Behavioral Health, Boca Raton, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Connecticut, Farmington, Connecticut, United States

and more 72 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath